Practice question

OS-9, osteosarcoma amplified 9, is evolutionarily conserved ER lumenal lectin originally identified as gene amplified in sarcoma but now recognized as central player in glycoprotein quality control triage. It contains single mannose-6-phosphate receptor homology domain that lacks phosphatase activity but binds high-mannose N-glycans after extensive mannose trimming, particularly exposed α1-6 mannose residue generated by EDEM family removing terminal α1-2 mannose from C-branch indicating prolonged retention. OS-9 constitutively complexes with adapter Sel1L and E3 ubiquitin ligase Hrd1 forming recognition module for soluble ERAD-L substrates such as null Hong Kong variant of α1-antitrypsin, misfolded tyrosinase and unassembled immunoglobulin heavy chains. By coupling glycan code reading to ubiquitination machinery, OS-9 transfers terminally misfolded clients to retrotranslocation channel, promotes polyubiquitination and delivery to cytosolic p97/VCP ATPase for proteasomal destruction. OS-9 also binds non-glycosylated clients via protein-protein interactions expanding surveillance. Its action prevents ER accumulation, attenuates unfolded protein response and maintains secretory pathway capacity under conditions of high load and stress requiring efficient degradation and clearance. Additional coordination with cellular stress pathways ensures fidelity, prevents aggregation, and links trafficking to growth control and proteostasis maintenance across diverse cell types and developmental stages.